Pharmacology

  • 27 topics
  • 1,274 questions
  • Library, from GHS 83.33 a month

Topics

  1. Adrenergic transmission and drugs

    88 questions

    • Identify pre- and post-junctional sites for drug action: α-methyltyrosine, reserpine, neuron-blocking drugs (guanethidine), α₂-autoreceptors, uptake inhibitors (cocaine, tricyclic antidepressants), and MAO and COMT inhibitors.
    • Describe noradrenaline synthesis (tyrosine hydroxylase as the rate-limiting step), vesicular storage (VMAT), release and inactivation (uptake 1/NET, uptake 2, MAO, COMT).
    • Relate receptor selectivity to representative agonists (adrenaline, noradrenaline, isoprenaline, phenylephrine, clonidine, dobutamine, salbutamol) and antagonists (prazosin, phentolamine, propranolol, atenolol, labetalol) at an introductory level.
    • Classify adrenoceptors (α₁, α₂, β₁, β₂, β₃) by location, G-protein coupling, second messenger and response.
    • Explain false transmitters (methyldopa → α-methylnoradrenaline) and indirectly acting sympathomimetic amines (tyramine, amphetamine, ephedrine), including the tyramine–MAOI interaction.
  2. Agonists, antagonists and types of antagonism

    37 questions

    • Classify antagonism: reversible competitive, irreversible (non-equilibrium) competitive, non-competitive, allosteric, chemical, pharmacokinetic and physiological (functional), with an example of each.
    • Explain the behaviour of a partial agonist given alone and in the presence of a full agonist.
    • Predict the effect of each type of antagonist on an agonist concentration–response curve (parallel rightward shift versus depression of the maximum).
  3. Chemotherapy of common haematological malignancies

    35 questions

  4. Cholinergic transmission and drugs

    74 questions

    • Identify the sites for drug action at the cholinergic synapse with an example drug for each: choline uptake (hemicholinium), vesicular storage (vesamicol), release (botulinum toxin), hydrolysis (reversible and irreversible anticholinesterases) and receptors.
    • Classify muscarinic receptors (M₁–M₅) by location, G-protein coupling, effector mechanism and function.
    • Describe organophosphate poisoning and its management with atropine and pralidoxime.
    • Describe muscarinic agonists (acetylcholine, methacholine, carbachol, bethanechol, pilocarpine): effects and uses.
    • Describe the synthesis (choline acetyltransferase), vesicular storage, release and hydrolysis (acetylcholinesterase, butyrylcholinesterase) of acetylcholine.
    • Describe muscarinic antagonists (atropine, hyoscine, ipratropium, tropicamide, oxybutynin): effects, uses and adverse effects; recognise anticholinergic toxicity.
  5. Drug distribution

    47 questions

    • Define apparent volume of distribution, calculate it (Vd = dose / C₀) and interpret large and small values.
    • Describe redistribution as a determinant of the duration of action (e.g. thiopental).
    • Describe body fluid compartments and the factors that determine drug distribution: blood flow, lipid solubility, plasma-protein and tissue binding, and barriers (blood–brain barrier, placenta).
    • Explain the clinical relevance of plasma-protein binding (albumin, α₁-acid glycoprotein) and of displacement interactions.
  6. Drug excretion

    44 questions

    • Define renal clearance and relate it to glomerular filtration rate.
    • Describe renal excretion: glomerular filtration, active tubular secretion and passive tubular reabsorption; explain the effect of urinary pH (e.g. urinary alkalinisation in salicylate poisoning).
    • Describe biliary excretion and enterohepatic circulation, and minor routes (lungs, breast milk).
  7. Drug interactions

    26 questions

    • Predict clinically important interactions from their mechanism (e.g. enzyme inducers with oral contraceptives, CYP inhibitors with warfarin, probenecid with penicillin).
    • Classify drug interactions as pharmaceutical, pharmacokinetic (absorption, distribution, metabolism, excretion) or pharmacodynamic (additive, synergistic, antagonistic).
  8. Drug metabolism (biotransformation)

    69 questions

    • Explain the time course and consequences of enzyme induction and inhibition.
    • Describe phase I (oxidation, reduction, hydrolysis) and phase II (glucuronidation, sulfation, acetylation, glutathione conjugation, methylation) reactions and the properties of their products.
    • Outline the effects of genetics (acetylator status, CYP2D6 polymorphism), age and liver disease on drug metabolism.
    • Explain the role of the cytochrome P450 system (CYP3A4, 2D6, 2C9, 2C19, 1A2) and name common enzyme inducers and inhibitors.
    • Describe prodrugs, and active and toxic metabolites (e.g. paracetamol and NAPQI).
  9. Drug permeation and absorption

    60 questions

    • Explain the factors affecting oral absorption; define bioavailability, bioequivalence and first-pass metabolism.
    • Apply the Henderson–Hasselbalch equation to predict the ionisation of weak acids and bases and explain ion trapping.
    • Compare the routes of drug administration (oral, sublingual, rectal, intravenous, intramuscular, subcutaneous, inhalational, topical, transdermal): advantages and limitations.
    • Describe the mechanisms by which drugs cross membranes: passive diffusion, aqueous pores, carrier-mediated transport (SLC and ABC transporters, including P-glycoprotein) and endocytosis.
  10. Drug therapy in kidney disease

    10 questions

  11. Ganglionic transmission and ganglion-blocking drugs

    28 questions

    • Describe ganglion stimulants (nicotine) and blockers (hexamethonium, trimetaphan, mecamylamine), and predict their effects on each organ from its dominant autonomic tone.
    • Describe nicotinic (NN) transmission in autonomic ganglia.
  12. History and scope of pharmacology

    36 questions

    • Distinguish pharmacology from related disciplines (pharmaceutics, pharmacognosy, medicinal chemistry, clinical pharmacy).
    • Define pharmacology and distinguish its branches: pharmacodynamics, pharmacokinetics, pharmacotherapeutics, toxicology and pharmacogenomics.
    • Outline the major milestones in the history of pharmacology, from materia medica and the isolation of active plant principles to the receptor concept (Langley, Ehrlich) and modern biologics.
  13. Integrative autonomic pharmacology and revision

    30 questions

    • Predict the net response to autonomic drugs in organs with dual innervation, including baroreceptor reflex responses (e.g. reflex bradycardia with phenylephrine; adrenaline reversal by α-blockade).
    • Solve problem-based cases that integrate pharmacodynamic, pharmacokinetic and autonomic principles.
  14. Non-adrenergic, non-cholinergic (NANC) and purinergic transmission

    57 questions

    • Relate purinergic pharmacology to drugs in use: methylxanthines (caffeine, theophylline), adenosine, dipyridamole and P2Y₁₂ antagonists (clopidogrel).
    • Describe nitric oxide as a NANC transmitter (e.g. penile erection, gastrointestinal relaxation) and link it to PDE5 inhibitors.
    • Describe purinergic signalling: release and inactivation of ATP and adenosine; P1 (A₁, A₂A, A₂B, A₃) and P2 (P2X ionotropic, P2Y metabotropic) receptors.
    • Define NANC transmission and co-transmission; give examples of NANC mediators (ATP, adenosine, nitric oxide, VIP, neuropeptide Y, substance P, CGRP) and the tissues in which they act.
  15. Organisation of the efferent nervous system

    50 questions

    • Describe the effects of sympathetic and parasympathetic activation on the major effector organs (eye, heart, blood vessels, bronchi, gut, bladder, glands) and the concept of dominant tone.
    • Outline the steps of chemical neurotransmission, Dale's principle, co-transmission and presynaptic modulation.
    • Compare the somatic efferent, autonomic (sympathetic and parasympathetic) and enteric nervous systems: anatomy, transmitters and receptors at each junction.
  16. Overview of drug discovery, development and regulation

    32 questions

    • Describe the role of pharmacovigilance and of the national regulatory authority (Food and Drugs Authority, Ghana) in approving and monitoring medicines.
    • Outline the stages of drug development: discovery, preclinical testing, clinical trial phases I–IV and post-marketing surveillance.
  17. Pharmacology of Diuretic Agents

    40 questions

  18. Quantitative analysis of antagonism and radioligand binding

    59 questions

    • Calculate dose ratio, KB or pA₂ from experimental data.
    • Describe saturation radioligand binding: total, non-specific and specific binding; derive Kd and Bmax; explain how non-specific binding is measured and why it is subtracted.
    • Define dose ratio and state the Schild equation (r – 1 = [B]/KB).
    • Describe competition binding experiments (IC₅₀) and the conversion of IC₅₀ to Ki (Cheng–Prusoff relationship).
    • Construct a Schild plot, determine pA₂ and interpret a slope of unity as evidence of simple competitive antagonism.
  19. Quantitative pharmacokinetics and dosing

    86 questions

    • Define clearance, elimination rate constant, half-life (t½ = 0.693 × Vd / CL) and area under the curve.
    • Describe the principles of therapeutic drug monitoring and the significance of a narrow therapeutic index.
    • Distinguish first-order from zero-order (saturation) kinetics, with examples (ethanol, phenytoin, high-dose aspirin).
    • Calculate loading and maintenance doses from Vd, CL, target concentration, dosing interval and bioavailability.
    • Explain steady state, accumulation and the time to reach steady state (about 4–5 half-lives).
    • Interpret plasma concentration–time curves for an intravenous bolus, an oral dose and a constant infusion using a one-compartment model.
  20. Receptor families and second-messenger effector systems

    46 questions

    • Describe the four receptor superfamilies (ligand-gated ion channels, G protein-coupled receptors, kinase-linked receptors, nuclear receptors): structure, time scale of response and a prototype example of each.
    • Explain the G-protein cycle and the main effector pathways: Gs/Gi–adenylyl cyclase–cAMP–protein kinase A; Gq–phospholipase C–IP₃/DAG–Ca²⁺–protein kinase C; direct regulation of ion channels.
    • Describe the second messengers (cAMP, cGMP, IP₅, DAG, Ca²⁺, nitric oxide) and explain signal amplification.
  21. Receptor regulation, desensitisation and tolerance

    47 questions

    • Define and distinguish desensitisation, tachyphylaxis and tolerance.
    • Describe the mechanisms of desensitisation: receptor uncoupling (phosphorylation by GRKs, PKA, PKC; β-arrestin binding), sequestration/internalisation, down-regulation and degradation, mediator depletion, increased drug metabolism and physiological adaptation.
    • Explain receptor up-regulation and supersensitivity (e.g. rebound after abrupt β-blocker withdrawal) and their clinical implications.
    • Distinguish homologous from heterologous desensitisation, with examples.
  22. Relation between binding and response: affinity and efficacy

    61 questions

    • Explain spare receptors (receptor reserve) and their effect on agonist potency and on the action of irreversible antagonists.
    • Construct and interpret graded concentration–response curves (arithmetic and log scale) and quantal dose–response curves (ED₅₀, TD₅₀, LD₅₀, therapeutic index, margin of safety).
    • Distinguish full agonists, partial agonists, inverse agonists and neutral antagonists; explain constitutive receptor activity.
    • Apply the law of mass action and occupancy theory (Hill–Langmuir equation) to relate drug concentration to receptor occupancy.
    • Define and distinguish affinity (KA/Kd), efficacy (intrinsic activity), potency (EC₅₀) and maximal effect (Emax).
  23. Somatic efferent transmission: the neuromuscular junction

    29 questions

    • Describe transmission at the skeletal neuromuscular junction (NM receptors, end-plate potential).
    • Distinguish non-depolarising (tubocurarine, atracurium, rocuronium) from depolarising (suxamethonium) neuromuscular blockers, including phase I and phase II block and reversal (anticholinesterases, sugammadex).
  24. Sources, nature and nomenclature of drugs

    56 questions

    • Identify the sources of drugs (plant, animal, mineral, microbial, synthetic and semi-synthetic, biotechnological) with at least one example of each, including medicines derived from plants used in Ghanaian traditional medicine.
    • Describe the physical nature of drugs (state, molecular size, reactivity) and explain the significance of chirality and enantiomers for drug action.
    • Apply drug nomenclature correctly: chemical name, code name, generic (International Non-proprietary Name) and proprietary (brand) name; explain why generic prescribing is preferred.
    • Define drug, medicine, prodrug and placebo.
  25. Targets of drug action and drug–receptor interaction

    45 questions

    • Name the four main classes of protein target (receptors, ion channels, enzymes, carriers/transporters) and give an example drug acting on each.
    • Explain drug specificity, selectivity, structure–activity relationships and stereoselectivity.
    • Distinguish drugs acting on specific targets from those acting by non-specific physicochemical mechanisms (e.g. antacids, osmotic diuretics, chelating agents).
    • Describe the forces involved in drug–receptor interaction (ionic, hydrogen, van der Waals, hydrophobic, covalent) and relate bond type to reversibility and duration of action.
  26. The principle and pharmacology of coagulant and anticoagulant therapy

    11 questions

  27. Across the subject

    71 questions

Find your course

Type your course code or its title. We show you exactly what we hold for it.

Or browse by programme